Sugi Predict

Sugi Predict / Compounds / SCHEMBL1619259

SCHEMBL1619259

SCHEMBL1619259

CC(C)(C)OC(=O)NCCN1CC2CN(Cc3ccccc3)CC(C1)O2.Cc1cc(C)c(S(=O)(=O)O)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ DRD2 P14416 2/20 0.41
▸ NPFFR1 Q9GZQ6 1/20 0.41
▸ NPFFR2 Q9Y5X5 1/20 0.41
▸ SUCNR1 Q9BXA5 2/20 0.41
▸ SIGMAR1 Q99720 3/20 0.41
▸ TSHR P16473 3/20 0.40
▸ HTT P42858 1/20 0.40
▸ EPHX2 P34913 2/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ FAAH O00519 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1619333 0.89 DRD2 (0.49) CYP2D6DRD2NPFFR1NPFFR2SUCNR1
SCHEMBL1619685 0.85 DRD2 (0.38) DRD2TSHREPHX2OPRD1OPRK1
SCHEMBL1619059 0.83 SIGMAR1 (0.53) DRD2NPFFR1NPFFR2SIGMAR1KMT2A
SCHEMBL18463376 0.80 DRD2 (0.52) CYP2D6DRD2NPFFR1NPFFR2SUCNR1
SCHEMBL5072489 0.76 SIGMAR1 (0.47) CYP2D6SIGMAR1TSHRHTTFAAH
SCHEMBL31165348 0.74 NPFFR1 (0.49) DRD2NPFFR1NPFFR2SIGMAR1BCHE
SCHEMBL3440056 0.74 DRD2 (0.64) DRD2NPFFR1NPFFR2SUCNR1SIGMAR1
SCHEMBL31301273 0.74 DRD2 (0.64) DRD2NPFFR1NPFFR2SUCNR1SIGMAR1
SCHEMBL1618250 0.72 DRD2 (0.45) CYP3A4DRD2SIGMAR1
SCHEMBL2969477 0.71 GPR119 (0.45) OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181619-A1 POLYMER FUNCTIONAL FILM, PRODUCTION METHOD THEREOF, AND STACK OR DEVICE PROVIDED WITH POLYMER FUNCTIONAL FILM Fujifilm Corporation (JP) 2017-06-21 — — EP disclosed
US-20170152361-A1 FUNCTIONAL POLYMER MEMBRANE, PRODUCTION METHOD THEREOF, AND STACK OR DEVICE PROVIDED WITH FUNCTIONAL POLYMER MEMBRANE FUJIFILM CORPORATION (JP) 2017-06-01 — — US disclosed
US-7928225-B2 Oxabispidine compounds for the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2011-04-19 — — US disclosed
US-20100222335-A1 Process For The Preparation Of N,N'-Disubstituted Oxabispidines ASTRAZENECA AB (SE) 2010-09-02 — — US disclosed
EP-1554285-B1 CHEMICAL INTERMEDIATE ASTRAZENECA AB (SE) 2010-01-13 — — EP disclosed
US-20090062532-A1 Chemical Intermediate ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
US-20090054422-A1 New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2009-02-26 — — US disclosed
US-20080200673-A1 Process for The Preparation of Sulfonic Acid Salts of Oxabispidines ASTRAZENECA AB (SE) 2008-08-21 — — US disclosed
EP-1915380-A1 PROCESS FOR THE PREPARATION OF N,N´- DISUBSTITUTED OXABISPIDINES AstraZeneca AB (SE) 2008-04-30 — — EP disclosed
EP-1893619-A1 NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS AstraZeneca AB (SE) 2008-03-05 — — EP disclosed
WO-2004035592-A1 CHEMICAL INTERMEDIATE ASTRAZENECA AB (SE) 2004-04-29 — — WO disclosed
EP-1389212-A1 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS AstraZeneca AB (SE) 2004-02-18 — — EP disclosed
EP-1389213-A1 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS AstraZeneca AB (SE) 2004-02-18 — — EP disclosed
EP-1385850-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES AstraZeneca AB (SE) 2004-02-04 — — EP disclosed
US-6586670-B2 Multilayer conductive support; photosensitve layer FUJI PHOTO FILM CO., LTD. (JP) 2003-07-01 — — US disclosed
WO-2002083688-A1 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
WO-2002083690-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
WO-2002083689-A1 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
US-20020040728-A1 Photoelectric conversion device and method for producing same FUJIFILM CORPORATION (JP) 2002-04-11 — — US disclosed
EP-1180774-A2 Photoelectric conversion device and method for producing same FUJI PHOTO FILM CO., LTD. (JP) 2002-02-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200673-A1 Process for The Preparation of Sulfonic Acid Salts of Oxabispidines RPS3, RPS3A, STS CYP2D6 121/4885CYP3A4 657/4885DRD2 98/4885
US-20100222335-A1 Process For The Preparation Of N,N'-Disubstituted Oxabispidines ADH1C, ADH5, ADH1A CYP2D6 201/4885CYP3A4 444/4885DRD2 12/4885
US-20090054422-A1 New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias RYR1, KCNH1, CACNA1E CYP2D6 93/4885CYP3A4 1028/4885DRD2 553/4885
US-20090062532-A1 Chemical Intermediate NAT1, CYP2B6, CBR1 CYP2D6 44/4885CYP3A4 69/4885DRD2 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.